Dose Insider / Glossary / ELIXA

ELIXAThe heart trial of lixisenatide and its neutral result

Updated November 20, 2026 · 3 min read · Pfeffer et al., N Engl J Med 2015

ELIXA is the cardiovascular trial of lixisenatide, a short-acting GLP-1 medicine injected once a day.

13.4%Lixisenatide, main heart outcome, ~2 years
Main heart outcome, ~2 yearsELIXA, % of patientsLixisenatide13.4%Placebo13.2%Main heart outcome, ~2 yearsELIXA, % of patientsLixisenatide13.4%Placebo13.2%

Hazard ratio 1.02: no harm, and no benefit.

On this page

It enrolled 6,068 people with type 2 diabetes who had had a heart attack or a hospital stay for unstable angina in the previous 180 days, and followed them for a median of 25 months on lixisenatide or placebo. The main outcome occurred in 13.4% on lixisenatide and 13.2% on placebo: the drug was shown to be safe for the heart, but not to protect it. It was published in the New England Journal of Medicine in 2015.1

How the trial was run

ELIXA enrolled a very high-risk group: people within six months, or 180 days, of an acute coronary event such as a heart attack. Lixisenatide or placebo was added to the standard care in each country. The main outcome had four parts, one more than the later trials: cardiovascular death, heart attack, stroke, or hospital stay for unstable angina.1

The trial was large enough to test two things in order. First, that lixisenatide was not worse than placebo, with an upper bound of the hazard ratio below 1.3. Second, if that held, whether it was better, with an upper bound below 1.0.1

What it found

Pfeffer et al., 2015.1

Why the result differs from later trials

Later trials of other GLP-1 medicines found lower heart risk: LEADER for liraglutide, with a hazard ratio of 0.87, and SUSTAIN 6 for semaglutide, at 0.74.2,3 The trials do not explain the difference, and several things changed at once. ELIXA enrolled people right after an acute coronary event, used a four-part outcome and lasted about two years. Lixisenatide is also short-acting: a 2021 review classes it with exenatide twice daily as a short-acting agent, with weaker effects on overnight and fasting blood sugar than the long-acting medicines.4 The same review notes that the short-acting medicines keep their effect on stomach emptying during long-term treatment, while the long-acting ones lose part of it over time, so the two kinds work differently over a day.4 Which of these differences mattered most for heart outcomes cannot be settled from the trials themselves.

What it means today

ELIXA established early that a GLP-1 medicine could be given safely to people with recent heart disease. Its neutral result shows that heart benefit is not automatic for every drug of the class: each medicine has to show it in its own trial. EXSCEL, the trial of once-weekly exenatide in 14,752 people, also fell short of a clear benefit, with a hazard ratio of 0.91 that just missed statistical significance.5 When people compare GLP-1 medicines for heart protection, the evidence for liraglutide, semaglutide and dulaglutide comes from their own trials, not from ELIXA.2,3,6

Limits

The trial was funded by Sanofi, the maker of lixisenatide, and is registered as NCT01147250. It followed people for a median of 25 months and enrolled only people with a recent acute coronary syndrome, so it does not describe lower-risk patients.1 Our page on Ozempic and Mounjaro covers the weekly diabetes injections most used today.

Sources

  1. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med 2015;373:2247-2257. Funded by Sanofi; NCT01147250. doi:10.1056/NEJMoa1509225
  2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
  3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
  4. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
  5. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). N Engl J Med 2017;377:1228-1239. doi:10.1056/NEJMoa1612917
  6. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130. doi:10.1016/S0140-6736(19)31149-3

Related analyses

Log your doses, blood sugar and blood pressure in one place.

Open Dose Insider